Bemotrizinol Opens a Market, With a Sourcing Gate

FDA's June final order adds bemotrizinol under defined OTC sunscreen conditions, effective 9 August 2026, and provides 18 months of exclusivity for DSM and specified related parties. BASF separately announced co-exclusive U.S. supply rights under a DSM licence. The regulatory development is final, but it is not a finished-product launch.

The scarce asset is no longer simply knowing that a modern UV filter exists. It is sourcing the material on workable terms, formulating an acceptable product, completing required testing and releasing it through a dependable manufacturing process. The order permits certain sprays, but does not establish the same route for powders or formulas directly combined with aerosol propellant.

A focused brief around a wear problem may be more defensible than racing to print “new filter” on a carton. Buyers should ask about the finished product's tested protection, stability, format and supply readiness. Confidence is high in the order and supplier announcements; market-wide stock, pricing, allocation and commercial winners remain unverified. A monograph ingredient does not make a product “FDA approved,” and this event supplies no reef-safety claim.